In April 2025, the World Health Organization unveiled a global repository for National Essential Medicines Lists (nEMLs), enhancing access to critical healthcare data and supporting policymakers in updating their essential medicines lists. This development underscores the importance of temozolomide's inclusion in national lists, facilitating its availability in various countries.
In May 2025, the 25th WHO Expert Committee on Selection and Use of Essential Medicines convened to review and update the Model List of Essential Medicines. The committee's recommendations, published in September 2025, reaffirmed the inclusion of temozolomide, highlighting its continued relevance in treating glioblastoma multiforme.
In January 2026, the WHO published a fact sheet on essential medicines, emphasizing the need for these medicines to be available, affordable, and of assured quality at all times. This reinforces the global commitment to ensuring access to critical treatments like temozolomide.
In February 2026, the WHO released a report on the selection and use of essential medicines, providing updated guidance on the inclusion criteria and processes for the Model List. This report serves as a valuable resource for countries in maintaining and updating their national essential medicines lists.
In March 2026, the WHO highlighted the importance of essential medicines in achieving universal health coverage, stressing the need for continuous efforts to improve access to these medicines globally. This aligns with the ongoing initiatives to ensure that treatments like temozolomide are accessible to patients in need.
